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EDITORIAL COMMENT
Sudden Death in
Mitral Regurgitation:
Why Was I So Surprised?*
Blase A. Carabello, MD
Houston, Texas
In this issue of JACC, Grigioni et al. (1) report on 348
patients with mitral regurgitation due to a flail mitral leaflet.
During a four-year follow-up, 25 of these patients (7%) died
suddenly. I have had the opportunity to speak or write about
valvular heart disease on literally hundreds of occasions over
the past 20 years. While always emphasizing the risk of
sudden death in a patient with aortic stenosis, I am virtually
certain that I have never cautioned about the risk of sudden
death in mitral regurgitation. When I initially read Grigioni
et al.’s report (1), I was surprised and momentarily skeptical.
Why should the patient with mitral regurgitation be at risk
for sudden death? Then, as I reflected on the paper more
carefully, I recognized that when the five asymptomatic
patients who developed symptoms of heart failure before
sudden death were added to the pool, 20 of the 25 patients
who died suddenly had the symptoms of congestive heart
failure at some point in their illness before sudden death.
Scores of studies have demonstrated that the presence of
congestive heart failure from either ischemic or dilated
cardiomyopathy carries with it a high risk of sudden death.
Although the patients reported by Grigioni et al. (1) were
generally not as sick as those reported in heart failure
studies, they followed the same trend (i.e., worsening heart
failure class and lower ejection fraction were two of the
major predictors of sudden death). Thus, I believe that
the common thread that links the patient with mitral
regurgitation to the risk of sudden death is the presence
of heart failure compounded by the presence of left
ventricular dysfunction.
See page 2078
Risk of death due to coronary disease. It is hard to know
how many of these patients died as a result of coronary
disease as an alternative explanation for their sudden death.
In the group, the average age was 71 years of age, 84% were
male and 56% smoked. Surely there would be some risk of
sudden death from coronary disease in a study group so
constituted. Although the authors directly address this
question, in fact, seven patients were suspected of having
coronary disease and only four had it excluded on the basis
of autopsy or angiography; the other 14 were left in
question. Although these 14 patients apparently had no
signs or symptoms of coronary disease, the bain of coronary
disease is sudden death without any symptomatic or objec-
tive evidence that it is present. Thus, coronary disease may
have played a role, but I also believe that mitral regurgita-
tion and its manifestation of heart failure were primarily
operative. How should these new data affect our therapy for
patients with mitral regurgitation and flail leaflet?
Asymptomatic patients with evidence with left ventricu-
lar dysfunction. It is clear both from this study and
previous studies that such patients require an operation
irrespective of which form of mitral valve correction will
ultimately be performed (2). Without therapy, such patients
will develop irreversible left ventricular dysfunction and
have increased mortality and persistent heart failure after the
operation. The new data add the risk of sudden death to
such patients, making operation an even more obvious
choice. Therefore, in asymptomatic patients with mitral
regurgitation who have a decrease in ejection fraction
toward 0.60 (3) or an increase in left ventricular end-systolic
dimension toward 45 mm (4,5), or if they develop pulmo-
nary hypertension (and inevitable right ventricular dysfunc-
tion), the operation should be performed (6,7).
Symptomatic patients with normal ventricular function.
The current data emphasize that heart failure is heart failure
and its symptoms must be taken seriously. It is a clinical
syndrome based not simply on ventricular performance, but
rather on a constellation of signs and symptoms. Mortality
is increased even when pure diastolic dysfunction causes the
syndrome of heart failure (8), and now it is apparently also
true (1) that mortality is increased in heart failure in mitral
regurgitation even when systolic function is normal. The
key message here is that we should not be assuaged by
normal left ventricular ejection fraction and a small end-
systolic dimension, once even mild symptoms develop
(being a little symptomatic is like having a few termites).
The study further raises the question about what to do if
such a patient develops the symptoms of heart failure but is
easily treated medically. Several patients in the current study
died after apparently initially successful medical therapy.
The current study suggests that symptoms of mitral regur-
gitation may be similar in gravity to those of aortic stenosis.
That is, once a patient develops symptoms, he or she should
be considered to have moved into the symptomatic category
even if changes in medical therapy or life-style make the
symptoms abate. One possible exception to this aggressive
approach is in the patient with acute mitral regurgitation
where compensatory hypertrophy has not yet occurred. Such
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patients may go on to enjoy a long compensated period after
initial decompensation. Because acuteness was not ad-
dressed here, this issue cannot be settled.
Asymptomatic patients with normal left ventricular func-
tion with a high likelihood of valve repair. An operation
here can probably be performed at a 1% to 2% operative risk
and does not entail the future risks inherent to prosthetic
heart valves (9). As with our current approach to atrial septal
defect therapy, correction of mitral regurgitation can be
performed at low operative risk, without using prosthetic
material, to prevent subsequent complications from occur-
ring. Thus, “prophylactic repair” should be considered. To
adopt this strategy, the eventual surgical procedure per-
formed must be highly predictable. The atrial septal defect
analogy obviously breaks down if the patient receives an
unwanted prosthetic valve. Current data suggest predictabil-
ity may be as low as 80%, although this probably varies from
institution to institution (10).
Asymptomatic patients with normal left ventricular func-
tion in whom repair is less than likely. This is the most
difficult group of patients to strategize. It is obviously tragic
if an asymptomatic patient with normal left ventricular
function receives a prosthetic valve and then suffers a
complication from it. It must be noted that seven patients in
Grigioni et al.’s study (1) had sudden death after the
operation. Although we do not know what kind of opera-
tion was performed in these patients, it is likely that these
were cases in which a prosthesis was inserted. In any case,
although the operation diminishes the risk of sudden death
in mitral regurgitation, it obviously does not prevent it.
Therefore, at the current time it does not seem wise to
commit the group of patients least likely to benefit from the
operation (those asymptomatic patients with normal left
ventricular function in whom the operation is likely to result
in a prosthetic valve) to the operation. Here it is likely that
operative risk, prosthetic valve complications and postoper-
ative sudden death will overwhelm any advantage to the
operation in reducing sudden death.
Should these results be applied to patients with severe mitral
regurgitation from causes other than flail leaflet? The short
answer is there is no way to know. If there is some unknown
aspect of a flail leaflet that confers increased mortality, the
answer would be no; if it is the pathophysiologic mechanism
itself, the answer is probably yes. Further study is clearly
necessary.
Conclusions. Heart failure is bad. Whether it accrues from
systolic dysfunction, diastolic dysfunction or now from
mitral regurgitation, the symptoms of congestive heart
failure are a warning that the patient possessing them is at
risk of cardiac death and sudden cardiac death. The worse
the symptoms and the worse the left ventricular dysfunction,
the worse the prognosis. Even if symptoms are transient,
they may presage a disastrous outcome. The therapy for
valvular heart disease has evolved toward a progressively
more aggressive strategy for earlier and earlier surgery. The
study by Grigioni et al. (1) adds still greater momentum to
this trend.
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